相关临床试验
15
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
14
93.3%
终止
1
6.7%
暂无批准数据
- Xeris Biopharma filed a patent infringement lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics to protect its drug Recorlev from unauthorized generic versions. - The company maintains intellectual property protection through March 2040 and Orphan Drug Exclusivity until December 2028 for Recorlev. - Xeris shares fell 10.83% to $6.01 following the lawsuit announcement, despite the stock gaining 61.30% over the past year. - Analysts maintain a Buy rating with an average price target of $11.03, expecting earnings of 4 cents per share and revenue of $84.17 million for the upcoming report.
- The 2nd Peptide Formulation & Delivery Innovation Summit will take place June 24-26, 2025, in Boston, bringing together 18 industry experts to address formulation and delivery challenges. - Recent advancements in permeation enhancers, nanoparticle encapsulation, and structural modifications have made oral delivery of peptide therapeutics a clinical reality for developers. - The summit will feature presentations from companies including Eli Lilly, Novo Nordisk, AltrixBio, and Xeris Pharmaceuticals, covering oral, inhaled, intradermal, and parenteral delivery systems.
